Founder of Primrose Therapeutics, Inc., Eric K. Rowinsky presently is Chairman at Purple Biotech Ltd., Executive Chairman & President at Inspirna, Inc., Chief Scientific Officer of Clearpath Development Co. and Chief Medical Officer for Hummingbird Bioscience. Dr. Rowinsky is also Consulting Chief Medical Officer at Everest Medicines Ltd. and Consulting Chief Medical Officer at Oncotartis, Inc. and on the board of 8 other companies.

Dr. Rowinsky previously was Chairman for Navidea Biopharmaceuticals, Inc., Chief Executive Officer for Primrose Therapeutics, Inc., Chief Medical Officer of Champions Oncology, Inc., Chief Medical Officer & Executive Vice President at ImClone LLC, CMO, EVP & Head-Research & Development at Stemline Therapeutics, Inc., Director-Drug Development Institute at Cancer Therapy & Research Center Endowment, Director at Biogen Idec New Ventures, Inc., Advisor at Maxwell Asset Management LLC (US), Chairman-Early Drug Development at IDD, Inc., Principal at National Cancer Institute, Clinical Professor-Medicine at Texas University of Health Center at San Antonio, Associate Professor-Oncology at The Johns Hopkins University School of Medicine, Adjunct Professor at New York University School of Medicine and Professor at the University of Texas Health Science Center At San Antonio.

He received an undergraduate degree from New York University and a doctorate from Vanderbilt University School of Medicine.